company background image
ACRS

Aclaris Therapeutics NasdaqGS:ACRS Stock Report

Last Price

US$16.82

Market Cap

US$1.1b

7D

1.0%

1Y

62.2%

Updated

27 Jan, 2023

Data

Company Financials +

Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Mkt Cap: US$1.1b

ACRS Stock Overview

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.

ACRS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Aclaris Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aclaris Therapeutics
Historical stock prices
Current Share PriceUS$16.82
52 Week HighUS$18.96
52 Week LowUS$9.84
Beta0.58
1 Month Change8.59%
3 Month Change9.43%
1 Year Change62.20%
3 Year Change1,256.45%
5 Year Change-19.75%
Change since IPO52.22%

Recent News & Updates

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aug 25
Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

May 28
Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Path To Profitability

Feb 28
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Path To Profitability

How Much Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Do Insiders Own?

Dec 18
How Much Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Do Insiders Own?

Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?

Nov 27
Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?

Shareholder Returns

ACRSUS PharmaceuticalsUS Market
7D1.0%-0.5%2.3%
1Y62.2%5.4%-9.7%

Return vs Industry: ACRS exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: ACRS exceeded the US Market which returned -8.5% over the past year.

Price Volatility

Is ACRS's price volatile compared to industry and market?
ACRS volatility
ACRS Average Weekly Movement7.5%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: ACRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ACRS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201275Doug Manionhttps://www.aclaristx.com

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Aclaris Therapeutics, Inc. Fundamentals Summary

How do Aclaris Therapeutics's earnings and revenue compare to its market cap?
ACRS fundamental statistics
Market CapUS$1.12b
Earnings (TTM)-US$82.08m
Revenue (TTM)US$23.50m

47.7x

P/S Ratio

-13.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACRS income statement (TTM)
RevenueUS$23.50m
Cost of RevenueUS$82.44m
Gross Profit-US$58.94m
Other ExpensesUS$23.14m
Earnings-US$82.08m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.23
Gross Margin-250.80%
Net Profit Margin-349.26%
Debt/Equity Ratio0%

How did ACRS perform over the long term?

See historical performance and comparison